An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone

NCT01142518 · clinicaltrials.gov ↗

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: Interferon beta 1a

Sponsor

Merck KGaA, Darmstadt, Germany